Lupin is currently trading at Rs 886.40, up by 2.75 points or 0.31% from its previous closing of Rs 883.65 on the BSE.
The scrip opened at Rs 884.00 and has touched a high and low of Rs 891.20 and Rs 883.00 respectively. So far 22816 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 946.35 on 11-Oct-2013 and a 52 week low of Rs 557.10 on 19-Nov-2012.
Last one week high and low of the scrip stood at Rs 893.85 and Rs 865.00 respectively. The current market cap of the company is Rs 39788.64 crore.
The promoters holding in the company stood at 46.78% while Institutions and Non-Institutions held 43.52% and 9.69% respectively.
Lupin’s - US subsidiary, Lupin Pharmaceuticals, has launched its generic Rabeprazole Sodium delayed?release tablets, 20mg. The company had earlier received final approval from the US FDA for the same. Lupin’s Rabeprazole Sodium delayed?release tablets, 20mg, are the generic equivalent of Eisai Inc.’s Aciphex delayed?release tablets, 20mg, and are indicated for the treatment of Gastro esophageal reflux disease (GERD). Aciphex delayed?release tablets, 20mg, had annual U.S sales of approximately $ 864.3million (IMS MAT Jun 2013).
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1820.75 |
| Dr. Reddys Lab | 1270.95 |
| Cipla | 1333.55 |
| Zydus Lifesciences | 911.85 |
| Lupin | 2343.40 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: